US 12,258,347 B1
GLP-1R agonist and therapeutic method thereof
Bin Liang, Hong Kong (CN); Jinzi Jason Wu, Hong Kong (CN); and Bailing Yang, Hong Kong (CN)
Assigned to Ascletis Pharma (China) Co., Limited, Hong Kong (CN)
Filed by Ascletis Pharma (China) Co., Limited, Hong Kong (CN)
Filed on Sep. 13, 2024, as Appl. No. 18/885,065.
Claims priority of provisional application 63/673,461, filed on Jul. 19, 2024.
Claims priority of provisional application 63/603,854, filed on Nov. 29, 2023.
Claims priority of application No. 202311582240.2 (CN), filed on Nov. 24, 2023; application No. 202311686034.6 (CN), filed on Dec. 8, 2023; application No. 202410142451.2 (CN), filed on Jan. 31, 2024; application No. 202410202078.5 (CN), filed on Feb. 22, 2024; application No. 202410398964.X (CN), filed on Apr. 2, 2024; application No. 202410584679.7 (CN), filed on May 11, 2024; application No. 202410906296.7 (CN), filed on Jul. 5, 2024; and application No. 202411237013.0 (CN), filed on Sep. 4, 2024.
Int. Cl. C07D 471/04 (2006.01); A61K 31/437 (2006.01); A61K 31/4985 (2006.01); A61K 31/519 (2006.01); A61K 31/5415 (2006.01); A61K 31/675 (2006.01); C07D 519/00 (2006.01); C07F 9/6561 (2006.01)
CPC C07D 471/04 (2013.01) [A61K 31/437 (2013.01); A61K 31/4985 (2013.01); A61K 31/519 (2013.01); A61K 31/5415 (2013.01); A61K 31/675 (2013.01); C07D 519/00 (2013.01); C07F 9/6561 (2013.01)] 13 Claims
 
1. A compound or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of:

OG Complex Work Unit Chemistry